# OnCo record hpv-negative-head-and-neck-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hpv-negative-head-and-neck-cancer" ;
  schema:name "HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)"@en ;
  schema:alternateName "Tobacco-related head and neck cancer"@en, "HPV-negative oropharyngeal cancer"@en, "p16-negative head and neck cancer"@en ;
  schema:description "Head and neck cancers caused by tobacco and alcohol rather than HPV are harder to cure: surgery or cisplatin chemoradiation is the mainstay, immunotherapy given around surgery (KEYNOTE-689) or after it (NIVOPOSTOP) has begun to help, and pembrolizumab is the first treatment once the disease has spread."@en ;
  schema:url <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Head_and_neck_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Head_and_neck_cancer> ;
  onco:tag "subtype-page", "head-and-neck" ;
  onco:pipeline <https://onco.cc/drugs/ficerafusp-alfa/>, <https://onco.cc/trials/fortifi-hn01/>, <https://onco.cc/trials/nct06064877/>, <https://onco.cc/trials/nct06256588/>, <https://onco.cc/drugs/petosemtamab/>, <https://onco.cc/drugs/mrg003/>, <https://onco.cc/drugs/cetuximab-sarotalocan/>, <https://onco.cc/trials/nivopostop/> ;
  onco:standardOfCare <https://onco.cc/terms/hpv-p16/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-689/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/nivopostop/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/trials/bonner-cetuximab-rt/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-048/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/trials/extreme/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/trials/metronomic-vs-cisplatin-tmh/>, <https://onco.cc/trials/low-dose-nivolumab-tmh/>, <https://onco.cc/technologies/smoking-cessation-after-diagnosis/>, <https://onco.cc/technologies/alcohol-reduction-labelling/> .